HRP20231563T1 - 4-okso-3,4-dihidrotino[3,4-d]piridazinski spojevi kao inhibitori aldosoreduktaze i načini njihove upotrebe - Google Patents
4-okso-3,4-dihidrotino[3,4-d]piridazinski spojevi kao inhibitori aldosoreduktaze i načini njihove upotrebe Download PDFInfo
- Publication number
- HRP20231563T1 HRP20231563T1 HRP20231563TT HRP20231563T HRP20231563T1 HR P20231563 T1 HRP20231563 T1 HR P20231563T1 HR P20231563T T HRP20231563T T HR P20231563TT HR P20231563 T HRP20231563 T HR P20231563T HR P20231563 T1 HRP20231563 T1 HR P20231563T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorder
- compound according
- subject
- compound
- pharmaceutically acceptable
- Prior art date
Links
- CVMTWTKIHQZGJJ-UHFFFAOYSA-N O=C1C=2C(C=NN1)=CSC=2 Chemical class O=C1C=2C(C=NN1)=CSC=2 CVMTWTKIHQZGJJ-UHFFFAOYSA-N 0.000 title 1
- 239000003288 aldose reductase inhibitor Substances 0.000 title 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000007166 healthy aging Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Cosmetics (AREA)
Claims (12)
1. Spoj formule (I)
[image]
pri čemu,
R1 je CO2R2;
R2 je H;
X1je H;
X2 je H;
Y je C=O;
Z je
[image]
A1 je S;
A2 je N; i
R3 do R6 su neovisno vodik, halogen ili haloalkil;
ili njegova farmaceutski prihvatljiva sol ili solvat.
2. Spoj sukladno patentnom zahtjevu 1, naznačen time, da su svaki od R3, R5 i R6 vodik i da je R4 vodik, halogen ili haloalkil.
3. Spoj sukladno patentnom zahtjevu 1 ili 2, naznačen time, da je spoj
[image]
ili njegova farmaceutski prihvatljiva sol ili solvat.
4. Spoj sukladno patentnom zahtjevu 1 ili 2, naznačen time, da je spoj
[image]
ili njegova farmaceutski prihvatljiva sol ili solvat.
5. Spoj sukladno patentnom zahtjevu 1 ili 2, naznačen time, da je spoj
[image]
ili njegova farmaceutski prihvatljiva sol ili solvat.
6. Spoj sukladno patentnom zahtjevu 1 ili 2, naznačen time, da je spoj
[image]
ili njegova farmaceutski prihvatljiva sol ili solvat.
7. Farmaceutski pripravak koji sadrži spoj sukladno bilo kojem od zahtjeva 1-6 i farmaceutski prihvatljiv nosač.
8. Spoj sukladno bilo kojem od zahtjeva 1-6 za upotrebu u liječenju poremećaja kod subjekta, pri čemu je poremećaj ateroskleroza, dijabetička nefropatija, dijabetička neuropatija, dijabetička retinopatija, kardiovaskularne bolesti, periferne vaskularne bolesti, poremećaja angiogeneze, dijabetička komplikacija, oštećenja tkiva ili dijabetičke kardiomiopatije.
9. Spoj sukladno bilo kojem od zahtjeva 1-6 za upotrebu u liječenju kožnog poremećaja ili za liječenje subjekta s razvojem infarkta miokarda.
10. Neterapijska metoda za poticanje zdravog starenja kože, naznačena time, da se sastoji od primjene spoja prema bilo kojem od zahtjeva 1-6 na dermalni supstrat subjekta.
11. Spoj sukladno bilo kojem od zahtjeva 1-6 za upotrebu u usporavanju ili smanjenju starenja kože.
12. Spoj sukladno bilo kojem od zahtjeva 1-6 za upotrebu u liječenju poremećaja kod subjekta, pri čemu je poremećaj neuropatija; ili
za upotrebu u liječenju poremećaja kod subjekta, pri čemu je poremećaj retinopatija; ili
za upotrebu u liječenju poremećaja kod subjekta, pri čemu je poremećaj nefropatija; ili
za upotrebu u liječenju poremećaja kod subjekta, pri čemu je poremećaj kardiomiopatija.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352784P | 2016-06-21 | 2016-06-21 | |
| EP20188323.8A EP3757107B1 (en) | 2016-06-21 | 2017-06-21 | 4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231563T1 true HRP20231563T1 (hr) | 2024-03-15 |
Family
ID=60783884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231563TT HRP20231563T1 (hr) | 2016-06-21 | 2017-06-21 | 4-okso-3,4-dihidrotino[3,4-d]piridazinski spojevi kao inhibitori aldosoreduktaze i načini njihove upotrebe |
| HRP20201905TT HRP20201905T1 (hr) | 2016-06-21 | 2020-11-30 | Inhibitori aldoza reduktaze i postupci njihove upotrebe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201905TT HRP20201905T1 (hr) | 2016-06-21 | 2020-11-30 | Inhibitori aldoza reduktaze i postupci njihove upotrebe |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10150779B2 (hr) |
| EP (3) | EP4316603A3 (hr) |
| JP (3) | JP6895464B2 (hr) |
| CN (2) | CN109310674B (hr) |
| AU (3) | AU2017281082B2 (hr) |
| BR (1) | BR112018076244A2 (hr) |
| CA (1) | CA3025081A1 (hr) |
| DK (2) | DK3352754T3 (hr) |
| ES (2) | ES2836500T3 (hr) |
| FI (1) | FI3757107T3 (hr) |
| HK (1) | HK1259379A1 (hr) |
| HR (2) | HRP20231563T1 (hr) |
| HU (2) | HUE052101T2 (hr) |
| IL (3) | IL283809B2 (hr) |
| LT (2) | LT3757107T (hr) |
| MX (2) | MX2018016122A (hr) |
| PL (1) | PL3757107T3 (hr) |
| PT (2) | PT3757107T (hr) |
| RS (1) | RS61239B1 (hr) |
| SG (2) | SG11201810642XA (hr) |
| SI (2) | SI3352754T1 (hr) |
| WO (1) | WO2017223179A1 (hr) |
| ZA (1) | ZA201808506B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| CN109310674B (zh) * | 2016-06-21 | 2022-07-08 | 纽约市哥伦比亚大学理事会 | 醛糖还原酶抑制剂及其使用方法 |
| US11590131B2 (en) * | 2017-07-28 | 2023-02-28 | Applied Therapeutics, Inc. | Compositions and methods for treating galactosemia |
| WO2020167937A1 (en) * | 2019-02-12 | 2020-08-20 | Applied Therapeutics, Inc. | Methods for treating cutaneous aging |
| CA3132136A1 (en) * | 2019-04-01 | 2020-10-08 | Andrew Wasmuth | Inhibitors of aldose reductase |
| EP4041219A4 (en) * | 2019-10-08 | 2023-11-01 | Applied Therapeutics, Inc. | ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF PHOSPHOMANNOMUTASE-2 DEFICIENCY |
| WO2021202523A1 (en) | 2020-03-31 | 2021-10-07 | Applied Therapeutics, Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
| KR20230005944A (ko) | 2020-05-01 | 2023-01-10 | 어플라이드 테라퓨틱스 인크. | 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제 |
| WO2022197487A1 (en) * | 2021-03-18 | 2022-09-22 | Banavara MYLARI | Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0189272A3 (en) * | 1985-01-17 | 1987-08-19 | Fujisawa Pharmaceutical Co., Ltd. | New furanone derivatives, processes for preparation thereof and use thereof |
| CA1299178C (en) | 1985-11-07 | 1992-04-21 | Banavara Lakshmana Mylari | Heterocyclic oxophtalazinyl acetic acids |
| ES2032749T3 (es) | 1985-11-07 | 1993-03-01 | Pfizer Inc. | Acidos oxoftalazinil-aceticos heterociclicos. |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4868301A (en) * | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| WO1989006651A1 (en) * | 1988-01-19 | 1989-07-27 | Pfizer Inc. | 1h-indazole-3-acetic acids as aldose reductase inhibitors |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| US4954629A (en) | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| US5304557A (en) | 1989-12-15 | 1994-04-19 | Pfizer Inc. | Substituted oxoophthalazinyl acetic acids and analogs thereof |
| JPH0495025A (ja) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | アルドースリダクターゼ阻害剤 |
| CA2145640C (en) * | 1992-09-28 | 2001-01-30 | Banavara L. Mylari | Substituted pyrimidines for control of diabetic complications |
| CN1200106A (zh) | 1995-08-28 | 1998-11-25 | 美国家用产品公司 | 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药 |
| WO1999015529A1 (en) | 1997-09-23 | 1999-04-01 | Novo Nordisk A/S | MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| CZ300706B6 (cs) | 1998-03-31 | 2009-07-22 | The Institutes For Pharmaceutical Discovery, Inc. | Derivát indolalkanové kyseliny a lécivo pro prevenci nebo zmírnení chronických komplikací vznikajících z diabetes mellitus |
| EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| NZ528406A (en) | 2001-03-30 | 2004-03-26 | Pfizer Prod Inc | Pyridazinone aldose reductase inhibitors |
| DE60308996T2 (de) | 2002-01-23 | 2007-05-10 | Eli Lilly And Co., Indianapolis | Melanocortinrezeptoragonisten |
| WO2003105864A1 (en) | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| ATE437642T1 (de) * | 2002-06-14 | 2009-08-15 | Takeda Pharmaceutical | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| US20070021366A1 (en) | 2004-11-19 | 2007-01-25 | Srivastava Satish K | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use |
| CN101143868A (zh) | 2007-09-04 | 2008-03-19 | 北京理工大学 | 醛糖还原酶抑制剂结构及用途 |
| ES2613700T3 (es) | 2010-07-16 | 2017-05-25 | The Trustees Of Columbia University In The City Of New York | Inhibidores de la aldosa reductasa y usos de los mismos |
| US8916563B2 (en) * | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| CN102512407B (zh) | 2011-11-23 | 2014-05-21 | 中山大学 | 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用 |
| CN109310674B (zh) * | 2016-06-21 | 2022-07-08 | 纽约市哥伦比亚大学理事会 | 醛糖还原酶抑制剂及其使用方法 |
| US11329472B2 (en) | 2018-07-20 | 2022-05-10 | Texas Instruments Incorporated | Methods and apparatus to prevent undesired triggering of short circuit or over current protection |
-
2017
- 2017-06-21 CN CN201780038647.5A patent/CN109310674B/zh active Active
- 2017-06-21 EP EP23201547.9A patent/EP4316603A3/en active Pending
- 2017-06-21 LT LTEP20188323.8T patent/LT3757107T/lt unknown
- 2017-06-21 IL IL283809A patent/IL283809B2/en unknown
- 2017-06-21 PL PL20188323.8T patent/PL3757107T3/pl unknown
- 2017-06-21 WO PCT/US2017/038505 patent/WO2017223179A1/en active Application Filing
- 2017-06-21 HU HUE17816127A patent/HUE052101T2/hu unknown
- 2017-06-21 PT PT201883238T patent/PT3757107T/pt unknown
- 2017-06-21 HR HRP20231563TT patent/HRP20231563T1/hr unknown
- 2017-06-21 RS RS20201463A patent/RS61239B1/sr unknown
- 2017-06-21 EP EP20188323.8A patent/EP3757107B1/en active Active
- 2017-06-21 JP JP2018567299A patent/JP6895464B2/ja active Active
- 2017-06-21 IL IL304979A patent/IL304979A/en unknown
- 2017-06-21 FI FIEP20188323.8T patent/FI3757107T3/fi active
- 2017-06-21 BR BR112018076244-0A patent/BR112018076244A2/pt active Search and Examination
- 2017-06-21 MX MX2018016122A patent/MX2018016122A/es unknown
- 2017-06-21 SG SG11201810642XA patent/SG11201810642XA/en unknown
- 2017-06-21 AU AU2017281082A patent/AU2017281082B2/en active Active
- 2017-06-21 DK DK17816127.9T patent/DK3352754T3/da active
- 2017-06-21 EP EP17816127.9A patent/EP3352754B1/en active Active
- 2017-06-21 HU HUE20188323A patent/HUE064911T2/hu unknown
- 2017-06-21 CN CN202210711329.3A patent/CN115160339B/zh active Active
- 2017-06-21 SI SI201730529T patent/SI3352754T1/sl unknown
- 2017-06-21 SG SG10202012188VA patent/SG10202012188VA/en unknown
- 2017-06-21 SI SI201731462T patent/SI3757107T1/sl unknown
- 2017-06-21 ES ES17816127T patent/ES2836500T3/es active Active
- 2017-06-21 PT PT178161279T patent/PT3352754T/pt unknown
- 2017-06-21 DK DK20188323.8T patent/DK3757107T3/da active
- 2017-06-21 CA CA3025081A patent/CA3025081A1/en active Pending
- 2017-06-21 ES ES20188323T patent/ES2966094T3/es active Active
- 2017-06-21 LT LTEP17816127.9T patent/LT3352754T/lt unknown
-
2018
- 2018-04-24 US US15/961,288 patent/US10150779B2/en active Active
- 2018-11-06 US US16/182,169 patent/US10647726B2/en active Active
- 2018-12-10 IL IL263631A patent/IL263631B/en unknown
- 2018-12-18 ZA ZA2018/08506A patent/ZA201808506B/en unknown
- 2018-12-18 MX MX2021014938A patent/MX2021014938A/es unknown
-
2019
- 2019-01-31 HK HK19101747.3A patent/HK1259379A1/zh unknown
-
2020
- 2020-03-31 US US16/835,876 patent/US10870658B2/en active Active
- 2020-11-02 US US17/086,699 patent/US11498925B2/en active Active
- 2020-11-30 HR HRP20201905TT patent/HRP20201905T1/hr unknown
-
2021
- 2021-06-07 JP JP2021094883A patent/JP7368419B2/ja active Active
- 2021-06-09 AU AU2021203801A patent/AU2021203801B2/en active Active
-
2022
- 2022-10-13 US US18/046,205 patent/US20230312599A1/en active Pending
-
2023
- 2023-06-30 AU AU2023204218A patent/AU2023204218A1/en active Pending
- 2023-10-12 JP JP2023176883A patent/JP2023171614A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231563T1 (hr) | 4-okso-3,4-dihidrotino[3,4-d]piridazinski spojevi kao inhibitori aldosoreduktaze i načini njihove upotrebe | |
| HRP20221495T1 (hr) | Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita | |
| AR099354A1 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos | |
| EA201591050A1 (ru) | Имидазопиридиновые соединения | |
| HRP20171873T1 (hr) | Fluorinirani antagonisti integrina | |
| MX2020012310A (es) | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. | |
| ECSP14006132A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| EA201891553A1 (ru) | Ингибиторы syk | |
| HRP20110349T1 (hr) | Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma | |
| ECSP109953A (es) | Derivados de piridazinona | |
| ECSP11011276A (es) | Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma. | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| ATE534292T1 (de) | Spiroverbindungen und anwendungsverfahren dafür | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| EA201792072A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| BR112014029439A2 (pt) | derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos | |
| CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου | |
| FR2999086B1 (fr) | Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation | |
| BR112016001948A2 (pt) | antagonistas de v1a para tratar distúrbios do sono de desvio de fase | |
| FR2995784B1 (fr) | Composition cosmetique sous forme d'emulsion et procede de traitement cosmetique |